HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Legislating US Regulatory Pathway For Cannabinoids ‘Not End of The World’ – Gottlieb

Executive Summary

Former FDA commissioner says legislative carve-out for a regulatory pathway for cannabinoids is a better option than a rulemaking, which could take five years and “may not even work.” Cannabinoids market is “well far ahead of where the regulation is,” he says.

You may also be interested in...



Legislating Hemp As Dietary Ingredient: Wrapping US Market In A Bow, Or Tying DSHEA In Knots?

House legislation to exempt hemp-derived cannabinoids from FDA rule that an “article” previously studied or approved for use as drugs is not allowed for use in dietary supplements either resolves a conundrum or raises additional questions for the agency and the industry.

Biden Administration Pause On Pending Trump-Era Rules Stalls FDA Cannabinoids Guidance Progress

Among four FDA regulatory items withdrawn from OMB review is “Cannabidiol Enforcement Policy; Draft Guidance for Industry,” which the agency submitted in July 2020.

House Appropriators Stoke Flames For FDA Regulation On CBD In Supplements

House Appropriations subcommittee with FDA oversight makes clear in questions for Commissioner Gottlieb they support allowing use of constituent ingredients from hemp and cannabis plants in food and dietary supplement products. Members also press for approving US firms' applications for pharmaceuticals with cannabis-derived active ingredients. Gottlieb announces working group will guide FDA decisions on potential CBD-use rulemaking.

Topics

UsernamePublicRestriction

Register

RS151194

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel